In this issue:
HT, menopausal symptoms & QoL 12 months after RRSO
Optimal NACT cycles before IDS for epithelial ovarian cancer
Patient-reported outcomes for dostarlimab in mismatch repair-deficient/microsatellite instability-high advanced/recurrent endometrial cancer
Patient-reported outcomes for cemiplimab vs. chemo in recurrent cervical cancer
Fistula incidence in cervical cancer treated with bevacizumab
Incidence & predictive factors for LTSROC
Obesity & WATi in endometrial cancer
Chronic toxicity in intensity-modulated vs. conventional radiation therapy
TP53 sequencing & p53 IHC predict outcomes for bevacizumab + chemo in endometrial cancer
Vistusertib + anastrozole in hormone receptor−positive recurrent or metastatic endometrial cancer
Please login below to download this issue (PDF)